CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


IO-202 Dose EscalationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1156 IO-202 Dose Expansion B Wiki 1.00
drug1155 IO-202 Dose Expansion A Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D015477 Leukemia, Myelomonocytic, Chronic NIH 1.00
D007951 Leukemia, Myeloid, NIH 0.58
D015470 Leukemia, Myeloid, Acute NIH 0.50
D007938 Leukemia, NIH 0.41

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0012325 Chronic myelomonocytic leukemia HPO 1.00
HP:0012324 Myeloid leukemia HPO 0.58
HP:0004808 Acute myeloid leukemia HPO 0.50
HP:0001909 Leukemia HPO 0.28

There is one clinical trial.

Clinical Trials


1 A Phase I Study of IO-202 as Monotherapy and in Combination With Azacitidine in Relapsed/ Refractory AML With Monocytic Differentiation and in Relapsed/Refractory CMML

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D) and dose schedule as monotherapy and in combination with azacitidine (AZA).

NCT04372433 AML M5 AML M4 AML, Nos Acute Myelogenous Leukemia in Relapse Myelomonocytic Leukemia, Chronic Drug: IO-202 Dose Escalation Drug: IO-202 Dose Expansion A Drug: IO-202 Dose Expansion B
MeSH:Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Myelomonocytic, Chronic
HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Chronic myelomonocytic leukemia Leukemia Myeloid leukemia

Primary Outcomes

Description: Incidence of adverse events

Measure: Safety of IO-202 as measured by incidence of adverse events.

Time: From first dose of IO-202 to 30 days following last study treatment

Description: Severity of adverse events

Measure: Safety of IO-202 as measured by severity of adverse events.

Time: From first dose of IO-202 to 30 days following last study treatment

Description: Incidence dose interruptions and dose reductions

Measure: Tolerability of IO-202 as measured by incidence and duration of dose interruptions and dose reductions of study treatment

Time: From first dose of IO-202 to 30 days following last study treatment

Secondary Outcomes

Description: Maximum concentration (Cmax) of IO-202

Measure: To characterize the pharmacokinetics (PK) of IO-202 as defined by maximum plasma concentration (Cmax)

Time: Through study completion, an average of 1 year

Description: measure area under the curve (AUC) of IO-202

Measure: To characterize the PK of IO-202 as defined by area under the curve (AUC)

Time: Through study completion, an average of 1 year

Description: Measure anti-drug antibodies in plasma.

Measure: To evaluate the incidence of anti-drug antibodies against IO-202

Time: Through study completion, an average of 1 year

Description: Measure response rates in patients with anti-drug antibodies.

Measure: To measure rates of response to IO-202 in patients with anti-drug antibodies

Time: Through study completion, an average of 1 year

Description: Measure response rates by bone marrow examination of blast percentage.

Measure: Measure response rates in patients treated with IO-202 or IO-202 in combination with AZA

Time: Through study completion, an average of 1 year

Other Outcomes

Description: Measure changes in numbers of lymphocytes with study drug treatment

Measure: To assess changes in lymphocytes with IO-202 or IO-202 in combination with AZA

Time: Through study completion, a average of 1 year

Description: Measure changes in blood immune proteins with study drug treatment

Measure: To measure blood immune proteins with IO-202 or IO-202 in combination with AZA

Time: Through study completion, a average of 1 year

Description: Statistical correlation levels of target expression on leukemic blasts with response rate

Measure: To correlate target expression with response rates

Time: Through study completion, a average of 1 year

Description: Statistical correlation of target expression on leukemic blasts with adverse event rates

Measure: To correlate target expression with rates of adverse events

Time: Through study completion, a average of 1 year

Description: Measure immunophenotype of leukemic blasts from bone marrow aspirates after study treatment

Measure: To evaluate immunophenotype of leukemic blasts after study treatment.

Time: Through study completion, a average of 1 year


Related HPO nodes (Using clinical trials)


Protein Mutations 0
SNP 0